Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.

Google DeepMind, the artificial intelligence company behind the popular AlphaFold tool, has published the next generation of the application’s protein structure prediction software. The new tool can ...

A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But can we trust drugs designed by a mind that isn't human? Reading time 3 ...

Imagine this: you’re in the middle of an important project, juggling deadlines, and collaborating with a team scattered across time zones. Suddenly, your computer crashes, and hours of work vanish in ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...

Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI. The news comes as tech ...

Add Yahoo as a preferred source to see more of our stories on Google. In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min In addition to news coming out ...

As Isomorphic Labs aims its artificial intelligence tools at drug development, it’s setting up a new outpost in the biotech hub of Cambridge. Founded in 2021 as a spinoff of Alphabet AI company ...